Skip to main content
SpringerLink
Log in

Serum neopterin as a prognostic indicator in patients with breast carcinoma

  • Research Article
  • Published:
Central European Journal of Medicine

Abstract

Neopterin is a useful indicator of the activation state of the cellular immune system, and an elevated level predicts prognosis in different types of tumors. The aim of this study was to evaluate serum neopterin levels if it is viable predictor for prognosis in breast carcinoma patients. Serum neopterin was investigated in 56 breast carcinoma patients, 16 patients with benign breast lesions and 16 healthy women as controls. Neopterin was measured by ELISA (Enzyme-linked immunosorbent assay). The clinicopathological parameters were determined by reviewing both medical charts and pathological records. All patients had been followed-up until September 2009 or death.The mean serum neopterin concentrations were 8.5 ± 5.2 nmol/L in patients with breast carcinoma, 6.5±3.1 nmol/L in patients with benign breast lesion and 8.1 ± 1.9 nmol/L in healthy volunteers (p>0.05). Elevated neopterin levels were significantly correlated with age, elevated serum CRP level, advanced stage and presence of the distant metastases (p<0.05). Overall survival was significantly shorter in patients with a serum neopterin level >10 nmol/L than patients with neopterin <10 nmol/L level (56 months vs. 76 months, p=0.011). Increased preoperative serum neopterin concentrations are associated with a poor prognosis in patients with breast carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fuchs D, Weiss G, Wachter H. Neopterin, biochemistry and clinical use as a marker for cellular immune reactions. Int Arch Allergy Immunol 1993; 101: 1–6

    Article  PubMed  CAS  Google Scholar 

  2. Wachter H, Fuchs D, Hausen A, Reibnegger G, Werner ER. Neopterin as marker for activation of cellular immunity: immunologic basis and clinical application. Adv Clin Chem 1989; 27: 81–141

    Article  PubMed  CAS  Google Scholar 

  3. Fuchs D, et al. Neopterin as a marker for activated cell-mediated immunity: application in HIV infection. Immunol Today 1988; 9: 150–5

    Article  PubMed  CAS  Google Scholar 

  4. Denz H, Griinewatd K, Thaler J, Huber H, Fuchs D, Hausen A, Reibnegger G, Werner ER, Wachter H. Urinary neopterin as a prognostic marker in haematological neoplasias. Pteridines 1989; 1: 167–170

    Google Scholar 

  5. Melichar B, Solichová D, Melicharová K, Malírová E, Cermanová M, Zadák Z. Urinary neopterin in patients with advanced colorectal carcinoma. Int J Biol Markers 2006; 21: 190–198

    PubMed  CAS  Google Scholar 

  6. Sucher R, Schroecksnadel K, Weiss G, Margreiter R, Fuchs D, Brandacher G. Neopterin, a prognostic marker in human malignancies. Cancer Letters 2009; June 3

  7. Murr C, Bergant A, Widschwndter M, Heim K, Schrocksnadel H, Fuchs D. Neopterin is an independent prognostic variable in females with breast cancer. Clinical Chemistry 1999, 45; 11: 1998–2004

    PubMed  CAS  Google Scholar 

  8. Frick J, Aulitzky W, Fuchs D, Hausen H, Joos H, Reibnegger G, et al. The value of urinary neopterin as an immunological parameter in patients with malignant tumors of the genitourinary tract. Urol Int 1985; 40: 155–9

    Article  PubMed  CAS  Google Scholar 

  9. Melichar B, Solichova D, Svobodova I, Urbanek L, Melicharova K. Urinary Neopterin in Patients with upper Gastrointestinal, Biliary and Pancreatic Carcinomas. Pteridines 2006: 17; 20–24

    CAS  Google Scholar 

  10. World Health Organization. Deaths by cause, sex and mortality stratum in WHO regions, estimates for 2002. Available online at: http://www.who.int/whr/2004/annex/topic/en/annex-2-en.pdf. 2009; January 12

  11. Yildirim Y, Gunel N, Coskun U, Pasaoglu H, Aslan S, Cetin A. Serum neopterin levels in patients with breast cancer. Med Oncol 2008; 25: 403–407

    Article  PubMed  Google Scholar 

  12. Berdowska A and Zwirska-Korczala K. Neopterin measurement in clinical diagnosis. J of Clinical Pharmacy and Therapeutics 2001; 26: 319–329

    Article  CAS  Google Scholar 

  13. Honlinger M, Fuchs D, Hausen A, Reibnegger, G, Schonitzer D, Werner ER, et al. [Serum neopterin determination for the additional safeguarding of blood transfusions. Our experiences with 76,587 blood donors]. Dtsch Med Wochenschr 1989;114:172–6

    Article  PubMed  CAS  Google Scholar 

  14. Melichar B, Solichova D, Freedmans RS. Neopterin as an indicator of immune activation and prognosis in patients with gynecological malignancies. Int J Gynecol Cancer 2006; 16: 240–252

    Article  PubMed  CAS  Google Scholar 

  15. Hausen A, Bichlker A, Fuchs D, Hetzel H, Reibnegger G, Wachter H. Neopterin, a biochemical indicator of cellular immune reaction, in the detection and control of patients with neoplastic diseases. Cancer Detect Prev 1985; 8: 121–8

    PubMed  CAS  Google Scholar 

  16. Bayram M, Bayram O, Boyunaga H, Guler Ozer. A research on the level of urine neopterin to see if it may provide a vital clue for a provisional diagnosis of breast cancer in menopausal women. Maturitas 2009; 48: 432–437

    Article  CAS  Google Scholar 

  17. Girgin G, Sahin T, Fuchs D, Kasuya H, Yuksek O, Tekin E, Baydar T. Immune system modulation in patients with malignant and benign breast disorders: tryptophan degradation and serum neopterin. Int J Biol Markers 2009; 11: none (Epub ahead of print)

  18. Hoffmann G, Wirleitner B, Fichs D. Potential role of immune system activation-associated production of neopterin derivatives in humans. Inflamm Res 2003; 52: 313–321

    Article  PubMed  CAS  Google Scholar 

  19. Melicharova K, Kalabova H, Kromova L, Urbanek L, Solichova D, Melichar B. Effect of comorbidity on urinary in patients with breast carcinoma. Eur J Cancer Care (Engl) 2009;13 (Epub ahead of print)

  20. Yoshida N, Ikemoto S, Narita K et al. Serum neopterin levels in renal cell carcinoma. Pteridines 2000; 11: 133–136

    CAS  Google Scholar 

  21. Schuler M, Peschel C, Schneller F et al. Immunomodulatory and hematopoietic effects of recombinant human interleukin-6 in patients with advanced renal cell cancer. J. Interferon Cytokine Res 1996; 16: 903–910

    Article  PubMed  CAS  Google Scholar 

  22. Murr C, Fuith LC, Widner B, Wirleitner B, Baier-Bitterlich G, Fuchs D. Increased neopterin concentrations in patients with cancer: indicator of oxidative stress? Anticancer Res. 1999;19(3A):1721–8

    PubMed  CAS  Google Scholar 

  23. Weiss G, Fuchs D, Hausen A, Reibnegger G, Werner ER, Werner-Felmayer G, Semenitz E, Dierich MP, Wachter H. Neopterin modulates toxicity mediated by reactive oxygen and chloride species. FEBS Lett. 1993; 19: 89–92

    Article  Google Scholar 

  24. Widner B, Baier-Bitterlich G, Wede I, Wirleitner B, Fuchs D. Neopterin derivatives modulate the nitration of tyrosine by peroxynitrite. Biochem Biophys Res Commun. 1998 Jul 20;248(2): 341–6

    Article  PubMed  CAS  Google Scholar 

  25. Weinberg F, Chandel NS. Reactive oxygen speciesdependent signalling regulates cancer. Cellular and Molecular Life Science 2009; Dec;66(23):3663–73. Epub 2009 Jul 24. Review

    Article  CAS  Google Scholar 

  26. Murr C, Berchtold J, Norer B, Waldhart E, Wachter H, Fuchs D. Neopterin as a prognostic parameter in patients with squamous-cell carcinomas of the oral cavity. Int J Cancer 1998; 79: 476–480

    Article  PubMed  CAS  Google Scholar 

  27. Djordjevic VB, Stojanovic I, Cosic V, Zvezdanovic L, Deljanin-Ilic M, Dimic S, Kundalic B, Cvetkovic T, Jevtovic-Stoimenov T. Serum neopterin, nitric oxide, inducible nitric oxide synthase and tumor necrosis factor-α levels in patients with ischemic heart disease. Clin Chem Lab Med 2008; 46: 1149–1155

    Article  PubMed  CAS  Google Scholar 

  28. Schobersberger W, Hoffman G, Grote J, Wachter H, Fuchs D. Induction of inducible nitric oxide synthase expression by neopterin in vascular smooth musclecells. FEBS Lett 1995; 377: 461–4

    Article  PubMed  CAS  Google Scholar 

  29. Moncada S, Higgs A. The L-arginine -nitric oxide pathway. N Engl J Med 1993; 329: 2002–12

    Article  PubMed  CAS  Google Scholar 

  30. Knowles RG, Moncada S. Nitric oxide sythases in mammals. Biochem J 1994; 298–58

  31. Nakamura Y, Yasuoka H, Tsujimoto M, Yoshidome K, Nakahara M, Nakao K, Nakamura M, Kakudo K. Nitric oxide in breast cancer: Induction of vascular entothelial growth factor-C and correlation with metastasis and poor prognosis. Clin Cancer Res 2006; 12: 1201–1207

    Article  PubMed  CAS  Google Scholar 

  32. Ambs S, Merriam WG, Ogunfusika MO, Bennett WP, Ishibe N, Hussain SP, Tzeng EE, Geller DA, Billiar TR, Harris CC. p53 and vascular endothelial growth factor regulate tumor growth on NOS2-expression human carcinoma cells. Nat Med 1998; 4: 1371–6

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 2nd General Surgery Clinics, Ankara Numune Training and Research Hospital, 06100, Ankara, Turkey

    Belma Kocer, Umit Turan, Suleyman Surmeli, Buket Altun, Osman Cem Yilmaz & Omer Cengiz

  2. Department of Microbiology, Ankara Numune Training and Research Hospital, 06100, Ankara, Turkey

    Sabahat Aksaray

Authors
  1. Belma Kocer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Umit Turan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Suleyman Surmeli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Buket Altun
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sabahat Aksaray
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Osman Cem Yilmaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Omer Cengiz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Belma Kocer.

About this article

Cite this article

Kocer, B., Turan, U., Surmeli, S. et al. Serum neopterin as a prognostic indicator in patients with breast carcinoma. cent.eur.j.med 5, 544–550 (2010). https://doi.org/10.2478/s11536-010-0017-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2478/s11536-010-0017-6

Keywords

Search

Navigation